Posted by Michael Wonder on 13 Dec 2024
Tolebrutinib designated breakthrough therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
13 December 2024 - Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis.
The US FDA has granted breakthrough therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis.
